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One of the most striking phenomena to the student of virus diseases 
is the occurrence of variants.  This phenomenon  is of particular impor- 
tance in that several such variants are being used for the immunization 
of man.  The two classical examples of the use of attenuated forms of 
virus for human vaccination are vaccinia and the fixed virus of rabies. 
The origin of vaccinia virus is a moot point, but it is almost universally 
considered to be a  variant of smallpox obtained by passage through 
the cow.  This virus was found as such in nature.  The fixed virus 
of rabies was produced by serial propagation in  rabbit  brain.  By 
this procedure a variant was produced which had lost to a considerable 
extent its pathogenicity for man and dog. 
By means of a comparable method the virus of yellow fever has been 
modified (1).  By serial propagation in mouse brains its viscerotropic 
affinity is diminished.  A  highly virulent strain  can by this means 
be readily converted into a relatively avirulent one which nevertheless 
acts as an efficient immunizing agent.  This fact has been made use 
of in developing methods for immunizing man (2, 3). 
However, by serial propagation in mouse brains, the inherent neuro- 
tropic affinity of yellow fever virus is markedly enhanced, not only 
for the mouse, but also for the monkey (4, 5), and probably for man. 
This increased neurotropism has rendered the virus potentially dan- 
gerous for human vaccination.  Consequently a  search was made to 
find methods for modifying yellow fever virus--methods which would 
not only reduce its viscerotropism but would also diminish, or at least 
not augment, its neurotropism.  That this would be possible appeared 
from the evidence brought forward by  the work of Lloyd, Theiler, 
and Ricci (6), which indicated that by prolonged cultivation in a tissue 
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culture medium the viscerotropic affinity of a highly virulent strain 
of yellow fever virus was markedly diminished, without at the same 
time producing a  marked change in  the neurotropic affinity.  The 
virus  cultivated in  tissue  culture was  significantly less  neurotropic 
than the virus then in use for human vaccination.  This culture virus 
was consequently substituted (6)  for the French neurotropic strain 
in the method of vaccination used by Sawyer, Kitchen, and Lloyd (2). 
The attenuation of the viscerotropic affinity produced in vitro,  how- 
ever, was not deemed sufficient to warrant the use of this virus without 
additional protection by the immune serum. 
In the previous paper (7) we have presented evidence to show that 
by the prolonged cultivation in a medium containing minimal amounts 
of nervous tissue, both of the major affinities are greatly diminished. 
The virus obtained by propagation in this medium produced extremely 
mild reactions when inoculated subcutaneously into rhesus monkeys. 
Furthermore, the virus had lost the power of producing fatal encepha- 
litis when injected intracerebratly into  these animals.  The  ability 
to produce fatal encephalitis in monkeys was lost between the 89th 
and the 114th subcultures in vitro.  A comparison of the neurotropic 
affinities for mice, using the virus obtained from the ll4th and the 
176th subcultures, showed that the virus from the latter subculture 
was considerably less neurotropic than that from the earlier.  This 
attenuated virus acted in monkeys as an efficient immunizing agent 
to a subsequent subcutaneous inoculation of a highly virulent strain. 
The idea of using this virus without the simultaneous injection of 
immune serum was obvious.  However, before introducing this virus 
for human vaccination additional experiments were undertaken. 
Methods and Materials 
The virus used in this study was the so called virus 17 D,  which for a  long 
period had been cultivated in vitro in a  medium containing the tissues of chick 
embryos  from  which  the  head  and  spinal  cord  had  been  removed  (7).  The 
methods and materials used in cultivating the virus of yellow fever have been 
described in previous papers (6,  7).  The virus is present in the tissue cultures 
in rather low concentration.  In studying the immune response of monkeys to 
large amounts of virus, the requisite concentration of virus for inoculation pur- 
poses was  obtained by  utilizing brains  of mice  which  had  been  infected with 
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Vaccines for human  use  were  prepared  from infected  whole  chick embryos 
inoculated  with  culture  virus  by the  technique  of Elmendorf  and  Smith  (8). 
This insures a high concentration of virus.  Infected chick embryos were ground 
up in a mortar with normal human serum to make a 10 to 15 per cent suspension. 
Mter  centrifugation  this  suspension  was passed  through a  Seitz filter  and  the 
filtrate frozen and desiccated in tubes, each containing from 0.5 to 1.0 cc.  Aerobic 
and anaerobic cultures were made on the filtrate  to test  for bacterial sterility. 
The potency of the vaccine was tested as routine by titration  in mice by intra- 
cerebral inoculation. 
EXPERIMENTAL 
Response of Rhesus Monkeys to a Subcutaneous Inoculation of Various 
Amounts  of Virus.--Two experiments  were  performed  to  study  the 
response of rhesus monkeys to various amounts of virus. 
In the first of these experiments  eight monkeys were used.  The virus was 
titrated in mice, and in Table I  the estimated number of average lethal doses for 
mice which each monkey received are shown.  The first  two monkeys (Nos.  1 
and 2) were inoculated with a suspension of infective mouse brains prepared from 
mice inoculated  with  material  from the  216th  subculture.  The remaining  six 
monkeys were inoculated with  decimal dilutions  of the  supernatant  fluid from 
the  217th  subculture.  In the  blood  of five no  virus  was  demonstrated  after 
inoculation.  In three monkeys (Nos.  1, 2, and 4)  the presence of virus in the 
blood was shown for a  duration of 1, 2, and 3 days respectively.  Two animals 
(Nos. 1 and 8) responded with a febrile reaction of 1 day's duration, in one aDimal 
1 day after inoculation, and in the other 5 days.  All eight animals lived, and 
seven were shown to have developed neutralizing antibodies in their sera 1 month 
after inoculation.  There seemed  to be no correlation between  the titer  of the 
serum  antibodies  and  the  size of the  immunizing dose.  One  animal  (No.  6) 
failed to become immunized for reasons not apparent, and when inoculated later 
with a somewhat larger dose of the same tissue culture virus it readily responded 
with the production of antibodies.  The seven monkeys which showed a demon- 
strable antibody production were given a  test dose of French neurotropic virus 
administered intracerebrally.  This method of testing the immunity of a monkey 
is far more severe than that of inoculating an animal intraperitoneally with the 
highly virulent Asibi virus, which is generally used.  Four of the animals (Nos. 2, 
3, 7, and 8) responded to this immunity test with a febrile reaction; two of these 
developed signs of encephalitis  (Nos. 3 and 8), one of which (No. 8) died on the 
7th  day  of  yellow  fever  virus encephalitis.  Three  normal  control  monkeys 
inoculated intracerebrally  with  the same virus preparation  died  of encephalitis 
in 7 to 9 days.  It may be significant that the two animals which showed signs 
of encephalitis following the test dose of neurotropic virus were those which also 
showed the least amount of neutralizing antibodies. 790  IM~IYI~IZATION  AGAINST  YELLOW  ~EVER 
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The influence of the  quantity of virus in  the immunizing dose on 
the resulting immunity was tested in a  second experiment essentially 
the same as the above. 
Six monkeys were inoculated  subcutaneously  with 1.0 cc. of decimal dilutions 
of the supernatant fluid of the 215th subculture of the virus in chick embryo tissue. 
Titration  of  the  virus  by intracerebral  inoculation  of mice  showed  that  the 
monkeys were  inoculated  with  0.2  to  20,000 minimum lethal  doses  for mice. 
Two animals  (Nos.  14 and  16) had a  febrile reaction,  one  (No.  14)  of 1 day's 
duration on the 4th day, and the other (No. 16) of 3 days' duration commencing 
on the  5th day after inoculation.  All  the animals  lived.  The antibody titer 
TABLE  II 
Antibody Response of Rhesus Monkeys Inoculated Subcutaneously with  Varying 
Amounts of Virus 
! 
Inoculum  [  Serum antibody titer 
t 
Monkey  Sub-  No.  No. of  Before  Weeks after inoculation 
culture  linoculation[  mouse linocu~on  ~.L.v.  4  6  S  12 
11  2  5  20,000  1:8  --*  1:4 
12  2,000  1:4  1:3 
13  200  1:2  1:240 
14  20  1:2  1:28 
15  2.0  1:2  1:4 
16  0.2  1:8  1:26 
* Not tested. 
of sera  obtained  1  and  3  months  after  immunization  was  determined.  The 
results showed that the antibody titer of the sera obtained  3 months after vacci- 
nation was appreciably  higher  than that obtained after 1 month in four of the 
six animals.  These results  are shown in Table  II.  Included in  this table are 
results of titrations on the sera of two additional monkeys (Nos. 9 and 10) obtained 
4,  6, and 8 weeks after vaccination.  These two monkeys had been  inoculated 
subcutaneously  with  1.0 cc. of a  tenfold  dilution  of a  virus preparation repre- 
senting  the  227th  subculture.  Some  of  this  preparation  was  later  used  for 
human inoculation.  As routine in immunizing animals, we have taken the serum 
antibody titer 1 month after vaccination as an index of the efficacy of the method 
of immunization.  From the results on these animals it is obvious that an entirely 
erroneous conclusion may be obtained  by using this arbitrary time interval,  and 792  I-M'MUIWIZATION  AGAINST  YELLOW  I~EVER 
it is possible that had the antibody response of an our animals been determined 
over a longer period of time following  inoculation, higher titers would have been 
found than those recorded throughout this and the previous paper (7). 
From the  results  of  these  experiments  undertaken  to  determine 
what influence the quantity of virus in the immunizing inoculation 
has on the resulting immunity, the conclusion seems warranted that 
even minimal quantities have the ability to produce an infection and 
consequently  the  production  of  antibodies  and  immunity.  Both 
monkeys (No.  8,  Table  I,  and No.  16,  Table  II),  inoculated with 
only fractions of an average lethal dose for mice, developed antibodies. 
This result seems to suggest that the monkey is probably more sus- 
ceptible  to  the  virus  than  the  mouse,  or  at  least  more  uniformly 
susceptible.  Some mice, of the  so  called Swiss strains used in our 
work, will become infected even when inoculated with fractions of an 
average lethal dose.  This result is to be expected from the method 
of determining the average  lethal  dose,  which by definition is  the 
amount of virus which kills half the mice inoculated within a specified 
period of time. 
Time of Appearance of Immunity in Monkeys Following  Inoculation. 
--The  time  after inoculation when  immunity is  developed  can  be 
determined by two methods.  The first is the determination of the 
time after inoculation when demonstrable antibodies appear  in the 
blood.  Antibodies were shown to be present as early as 7 days after 
inoculation in several monkeys investigated.  After 14 days all ani- 
mals studied had demonstrable antibodies.  The second method of 
determining the  time  of  development of  immunity is  to  inoculate 
monkeys with a virulent virus at various intervals after the immuniz- 
ing inoculation.  Table III shows the result of such an experiment. 
The virus preparation used for the immunity test was a frozen and desiccated 
serum obtained from a monkey at the height of infection with the virulent Asibi 
strain.  This preparation had been found to be virulent when tested on numerous 
occasions.  All the monkeys used in this experiment were first inoculated subcu- 
taneously with 1 cc. of a 1 in 10 dilution of the tissue culture vaccine.  The first 
monkey in the series (No. 17) received the test dose of Asibi virus immediately 
after the vaccine.  In the other monkeys the interval between the vaccine and 
the test dose was 1, 3, 5, 7, and 14 days.  Two monkeys (Nos. 25 and 26)were 
inoculated with the test virus alone to serve as controls.  Following  the inomfla- MAX  THEILER AND  HUGH H.  SMITH  793 
tion of the Asibi virus, the monkeys were bled daily and the sera obtained injected 
intracerebrally  into mice to determine  the presence of virus in the circulation. 
Monkey  17,  which  was  inoculated  simultaneously  with  the  vaccine  and  the 
Asibi virus, died of typical yellow fever 3 days after inoculation.  Two monkeys 
(Nos.  18 and  19)  which received the test virus  1 and 3 days after the vaccine 
died  of yellow fever 4  and  6  days respectively after the  test.  Monkey 20,  in 
which the interval between the immunizing and the test inoculation was 5 days, 
TABLE  III 
The Response of Rhesus Monkeys to a Tea Dose of Virulent Asibi Virus Injected at 
Various Time Intervals after Vaccination with Tissue Culture Virus 17 D 
Time interval 
between vac- 
cination  and 
Test for virus  in circulating 
blood: mortality ratio in mice 
inoculated with monkey serum 
Days after  in~ection  of  Asibi 
virus 
1  2  3  4  5  6  7 
3/6 7/7 [5/5 
! 
0/7 7/716/6 
6/6s/sw 
~on- 
key 
No.  immunity test 
with Asibi virus 
days 
17  0 
18  1 
19  3  0/6 
20  5  0/7 
21  7  0/6 
22  7  0/6 
23  14  {)/6 
24  14  ()/6 
25  Unvaccinated  1/4 
control 
26  "  "  1/6 
3/7 o/c 1/5 o17 o/5 o/c 
o/3 o17 [}/6 o/5 o/5 
o/5 0/7 [}/6  017 o/s 
0/4 0/~ [)/4 {)/6 0/5 
o/5 0/~ [}/2 [}/6  0/5 
8/8 8/8 ~IS  o16 o/6 o/s 
s/6 s/s 5/6 3/6 0/5 o/~ 
Fever 
on days 
after 
inocu- 
lation 
3 
4 
4,  6 
22 
18 
3, 4, 5 
Results 
•  --  . Died on 
3rd day 
Died on 
4th day 
Died on 
6th day 
Lived 
~c 
cc 
cc 
~c 
Presence of antibodies in 
serum after vaccination 
with virus 17 D 
7 days  14  days 
Negative  Positive 
cc  cc 
cl  lc 
Result inconclusive as three of six mice survived. 
showed a  febrile reaction but  lived.  In this  animal minimal amounts of virus 
were demonstrated in the circulation.  Four animals  (Nos. 21,  22,  23,  and 24), 
in which the intervals were 7 days and 14 days, all lived and showed no virus in 
their  Circulation  during  the  first  6  days  following the  test  inoculation.  The 
fevers of 1 day's duration on the 18th and 22nd days following inoculation regis- 
tered by two monkeys cannot be considered specific.  Neutralization tests with 
the sera obtained from these four animals  1 and 2 weeks after the immunizing 
injection showed that at the latter period of time demonstrable antibodies were 794  I"MMUNIZATION  AGAINST  YELLOW  ~FEVER 
present in all four animals.  The two control monkeys (Nos. 25 and 26) inoculated 
with  the  test virus alone unexpectedly lived.  Virus was demonstrated in the 
blood of both, in one animal (No. 25) for 3 days and in the other (No. 26) for 
5 days. 
In spite of the failure of the two control animals to die, the experi- 
ment is not without value.  Using presence or absence of circulating 
virus as an index of immunity, the conclusion seems warranted that 
a substantial immunity is present 1 week after the immunizing inocu- 
lation and a partial immunity in 5 days. 
A  Comparison of the Pathogenicity of the French Neurotropic Virus 
and the 17 D Strain of Culture Virus for Experimental Animals.--The 
two strains of yellow fever virus which have been used to date for the 
vaccination of man are the French virus, modified by serial mouse 
brain passage, and the Asibi virus, modified by cultivation in whole 
mouse embryo. 
Of these two, only the first has been used alone, without the simul- 
taneous injection of immune serum (3, 9-11).  The pathogenicity of 
the French neurotropic virus for experimental animals is known, and 
a  certain amount of information is available concerning its patho- 
genicity for man.  Rhesus monkeys inoculated intraspinally or intra- 
cerebrally with the French neurotropic virus invariably die of yellow 
fever virus encephalitis (4, 5).  Following extraneural inoculation this 
virus produces an infection which manifests itself by the production 
of  a  febrile reaction in approximately 50 per  cent of the  animals. 
In  Table  IV  are  summarized the  results  obtained  by  inoculating 
twenty-one  monkeys  by  various  extraneural  routes  with  varying 
amounts of French neurotropic virus.  Virus in the circulation, lasting 
for a period of 2 to 6 days, was invariably present; and approximately 
30  per  cent of  the  animals died of encephalitis.  By mouse  brain 
passage the viseerotropic affinity of the virus has been considerably 
diminished,  whereas the  neurotropie affinity  has  been  augmented. 
It is this enhancement of the neurotropie affinity which makes this 
virus potentially dangerous for human vaccination.  That this fear 
is justified has been proven by the occurrence of severe involvement of 
the central nervous system following its use for human vaccination. 
These neural accidents have occurred both when the virus was ad- 
ministered alone (10, 12) as well as when administered with immune MAX  THEILER  AND  HUGH  H.  SMITH  795 
It 
~!  i  I~  o  ~  ~o  ~  I  ~  I  ~~  I  I  I  I~  I 
"I 
~o 
o 
~o  -~-  - ~  ..... 
°1  .......  I 
~ .~  .~  .; 
~.~ 
i  NNN~  ~NNN3N 796  IMMUNIZATION  AGAINST  YELLOW  FEVER 
serum (13).  Not only does the French neurotropic strain occasionally 
produce severe neural involvement, but the systemic reaction of man 
to the virus when administered without immune serum is sufficiently 
severe in a  fair proportion of people to  contraindicate its use. 
The known pathogenic activities for experimental animals of the 
French neurotropic virus and virus 17 D are summarized in Table V. 
In all the points enumerated the French neurotropic virus is more 
pathogenic than the cultivated strain.  It is a noteworthy fact, how- 
ever, that though the French neurotropic virus is extremely  pathogenic 
TABLE  V 
A  Comparison of the Pathogenicity of French Neurotropic Virus  and  Virus  17 D 
for Experimental Animals 
Mice  Rltesus monkeys  Hedgehogs 
Virus  Average time 
of death after  Intracerebral  Extraneural inoculation  Subcutaneous 
intracerebral  inoculation  inoculation 
inoculation 
French neu- 
rotropic 
Tissue  cul- 
ture virus 
17 D 
days 
4-10 
8-20 
Fatal  en- 
cephalitis 
Non-fatal 
encepha- 
litis 
Fever in approximately 50 per 
cent of animals.  Virus pres- 
ent in circulating blood for 
a period of 2-6 days.  Fatal 
encephalitis  in  approxi- 
mately 30 per cent of ani- 
mals 
Occasional  fever.  Minimal 
amounts of virus  in the cir- 
culation: No deaths 
Death  from 
enceph- 
alitis with 
liver  ne- 
crosis 
Animals sur- 
vive 
for the nervous systems of all the susceptible experimental animals, 
the number of times the central nervous system has become involved 
in man folloMng the use of this virus for vaccination is  relatively 
small.  The danger of similar accidents occurring in man following 
the use of the strain cultivated in a medium poor in nervous tissue 
should accordingly be  negligible.  After  114  subcultures this  virus 
had lost its power of producing fatal encephalitis in monkeys.  That 
continued cultivation in chick embryo medium after the 114th  sub- 
culture leads to a further loss of neurotropism is shown by the intra- 
cerebral inoculation of mice with later subcultures.  From the results MAX  THEILER  AND  HUGH  H.  SMITH  797 
of these animal experiments it is felt that the virus grown in chick 
embryo tissue for more than 200 subcultures should be safe for human 
vaccination. 
Inoculation  of Immune Persons  with Tissue Culture  Virus 17 D.-- 
As the immune response in monkeys following vaccination with the 
virus grown for prolonged Periods in chick embryo tissue indicated 
that this response was comparatively mild, it seemed desirable to test 
the response in immune persons before using this virus for human 
vaccination.  In Table VI is shown the antibody production in four 
persons inoculated subcutaneously with a vaccine prepared from the 
227th subculture of the virus grown in chick embryo tissue.  One of 
TABLE  VI 
Antibody  Response in Immune  Persons to  a  Subcutaneous  Inoculation  of Tissue 
Culture Virus 17 D 
Inoculum 
Immune 
~er°n  I 
la ed 
--.  __  f~ 
cc. 
M  T  1.0:227 
H.S.  I.C  227 
T.F.  0.8  227 
• R'L"  0.5  227 
Serum antibody titer 
No.  of  Before 
mouse  inoCu- 
U.L.V.  lation 
330,00C  1:32 
330,00C  1:2 
70,00G  1:2 
44,00~  1:2 
Weeks after inoculation 
1:2 
1:6 
1:2 
2  3  4  5  6 
1:90  l:12t  1:110 
1:4  1:3  1:8  1:5 
I:1001:I001:10C 
1:25  1:20  1:34 
7  8  9 
1:80 
1:21 1:8 
10 
1:9~ 
them had an antibody titer of 1 in 32 before inoculation, as a result of 
an  attack  of  yellow fever  several years before.  The  three  other 
persons had been vaccinated previously, but the antibodies had almost 
entirely disappeared from their sera.  In all four there was a marked 
antibody response.  Apart from a slight local reaction at the site of 
inoculation no signs or symptoms were noticed. 
The antibody response in immune persons to a subcutaneous inocu- 
lation of virus grown for a  prolonged time in  chick embryo tissue 
differs markedly from the response produced by the French neuro- 
tropic virus and virus grown in mouse embryo tissue.  Lloyd, Theiler, 
and Ricci (6) found that the antibody titer in immune human beings, 
inoculated  with  the  two strains  of  virus  mentioned  above,  rose 798  IMMUNIZATION  AGAINST  YELLOW  FEVER 
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rapidly to  reach a  peak on  about  the  14th  day and  then  rapidly 
diminished,  so  that  the  titer  4  weeks after inoculation  tended to 
approximate its initial level.  The antibody response of immune per- 
sons to the virus grown in chick embryo tissue is much slower.  From 
the limited number of observations recorded in this paper, it would 
appear that the antibody titer rises gradually, the height of the rise 
not being reached until the 4th to the 8th week, when a slow decline 
sets in.  Even after 10 weeks the antibody titer has not fallen to its 
initial level. 
Inoculation of Non-Immune Persons with Tissue Culture Virus 17 D. 
--To date eight normal persons have been vaccinated with the 17 D 
culture virus.  The vaccines used were prepared from the 227th and 
the 229th subcultures.  The relevant observations on these persons 
are  shown in  Table VII.  The reactions at  the  site of inoculation 
were minimal.  Five persons had a febrile reaction, which in four of 
them occurred  from the 5th to the 7th days.  The highest temperature 
recorded was 37.4°C.  The febrile reactions were accompanied as a 
rule by slight headache and backache, which were not severe enough 
to prevent the subject from following his normal occupation. 
Investigations  on  the  appearance of  antibodies  showed  that,  2 
weeks after vaccination, demonstrable antibodies were present in the 
serum of all the six persons studied.  The sera from three showed no 
protective antibodies 1 week after vaccination.  The serum antibody 
titer has been studied in only two subjects.  In both the antibody 
titer was determined at intervals after vaccination.  The results tend 
to show that the antibody titer produced is very low.  No information 
is available as to  the duration of the immunity produced by vac- 
cination. 
The results obtained in the small number of persons vaccinated with 
the tissue culture virus are sufficiently encouraging to warrant a more 
extensive trial of the method. 
SUMM~RY 
The response of rhesus monkeys to a subcutaneous inoculation with 
varying amounts of virus modified by prolonged cultivation in vitro 
has been studied.  The tissue components of the medium consisted 
of chick embryo tissue containing minimal amounts of nervous tissue. 800  EWMUNIZATION AGAINST YELLOW FEVER 
The immunity produced in monkeys, as measured by the antibody 
titer developed, has no relation  to  the amount of virus inoculated. 
Monkeys inoculated subcutaneously with the tissue  culture virus 
are rendered immune to a  subsequent injection of a  highly virulent 
yellow fever virus.  This resistance is  already present  7  days after 
vaccination. 
The  subcutaneous  inoculation  of  the  culture  virus  into  immune 
persons leads to  a  substantial increase of the serum antibody titer. 
The results of vaccinating eight normal persons with culture virus 
are presented.  The reactions were minimal.  The highest tempera- 
ture recorded following vaccination was 37.4°C. 
The sera taken from the eight vaccinated persons 2 to 4 weeks after 
inoculation  with  the  tissue  culture  virus  showed  the  presence  of 
yellow fever antibodies. 
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